Redx Pharma PLC's (LON:REDX) Lisa Anson catches up with Proactive London with the latest on their clinical trial assessing RXC004 used alongside the Bristol Myers Squibb’s anti-PD-1 cancer drug OPDIVO.
There are now three patients dosed in its phase I trial with the primary objective of the study to evaluate the safety and tolerability of the regimen.
Results are expected in the second half of the year, which will be used to define dosing for a phase II clinical assessment of the combination, which is planned to get underway in the second half.